Academic Department of Radiation Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY.
Academic Department of Radiation Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY.
Int J Radiat Oncol Biol Phys. 2021 Apr 1;109(5):1232-1242. doi: 10.1016/j.ijrobp.2020.11.003. Epub 2020 Nov 7.
Low-dose-rate (LDR) brachytherapy and stereotactic body radiation therapy (SBRT) have both shown acceptable outcomes in the treatment of low- and intermediate-risk prostate cancer. Minimal data have been published directly comparing rates of biochemical control and toxicity with these 2 modalities. We hypothesize that LDR and SBRT will provide similar rates of biochemical control.
All low- and intermediate-risk patients with prostate cancer treated definitively with SBRT or LDR between 2010 and 2018 were captured. Phoenix definition was used for biochemical failure. Independent t tests were used to compare baseline characteristics, and repeated measure analysis of variance test was used to compare American Urologic Association (AUA) and the Expanded Prostate Cancer Index Composite (EPIC) scores between treatment arms over time. Biochemical control was estimated using the Kaplan-Meier method. Differences in acute and late toxicity were assessed via Pearson χ.
In the study, 219 and 118 patients were treated with LDR and SBRT. Median follow-up was 4.3 years (interquartile range, 3.1-6.1). All patients treated with LDR received 125.0 Gy in a single fraction. SBRT consisted of 42.5 Gy in 5 fractions. Five-year biochemical control for LDR versus SBRT was 91.6% versus 97.6% (P = .108). LDR patients had a larger increase in mean AUA scores at 1 month (17.2 vs 10.3, P < .001) and 3 months posttreatment (14.0 vs 9.7, P < .001), and in mean EPIC scores at 1 month (15.7 vs 13.8, P < .001). There was no significant difference between LDR and SBRT in late grade 3 genitourinary toxicity (0.9% vs 2.5%, P = .238); however, LDR had lower rates of late grade 3 gastrointestinal toxicity (0.0% vs 2.5%, P = .018).
Our data show similar biochemical control and genitourinary toxicity rates at 5 years for both SBRT and LDR, with slightly higher gastrointestinal toxicity with SBRT and higher AUA and EPIC scores with LDR.
低剂量率(LDR)近距离放疗和立体定向体部放疗(SBRT)在治疗低危和中危前列腺癌方面均显示出可接受的结果。直接比较这两种方法的生化控制率和毒性的数据很少。我们假设 LDR 和 SBRT 将提供相似的生化控制率。
我们收集了 2010 年至 2018 年间接受 SBRT 或 LDR 确定性治疗的所有低危和中危前列腺癌患者。采用 Phoenix 定义判断生化失败。采用独立 t 检验比较基线特征,采用重复测量方差分析比较治疗组之间随时间变化的美国泌尿外科学会(AUA)和前列腺癌指数综合评分(EPIC)。采用 Kaplan-Meier 法估计生化控制率。采用 Pearson χ 评估急性和晚期毒性的差异。
在这项研究中,219 例和 118 例患者分别接受 LDR 和 SBRT 治疗。中位随访时间为 4.3 年(四分位距,3.1-6.1)。所有接受 LDR 治疗的患者均接受单次 125.0 Gy 照射。SBRT 采用 5 次分割,每次 42.5 Gy。LDR 和 SBRT 的 5 年生化控制率分别为 91.6%和 97.6%(P =.108)。LDR 患者在治疗后 1 个月(17.2 对 10.3,P <.001)和 3 个月(14.0 对 9.7,P <.001)时 AUA 评分的平均增加幅度更大,在治疗后 1 个月(15.7 对 13.8,P <.001)时 EPIC 评分的平均增加幅度更大。LDR 和 SBRT 的晚期 3 级泌尿生殖系统毒性无显著差异(0.9%对 2.5%,P =.238);然而,LDR 的晚期 3 级胃肠道毒性发生率较低(0.0%对 2.5%,P =.018)。
我们的数据显示,SBRT 和 LDR 治疗 5 年的生化控制率和泌尿生殖系统毒性率相似,SBRT 组胃肠道毒性略高,LDR 组 AUA 和 EPIC 评分略高。